SCHEMBL473376

SCHEMBL473376

CCN(CC)C(C)c1ccccc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
ADRA2A P08913 2/20 0.38
KCNH2 Q12809 2/20 0.38
PGR P06401 1/20 0.38
ADRA2B P18089 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
TSHR P16473 2/20 0.35
ALOX15 P16050 3/20 0.35
CYP3A4 P08684 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 3/20 0.34
KDM4E B2RXH2 3/20 0.33
BCHE P06276 3/20 0.33
HPGD P15428 3/20 0.33
CYP2D6 P10635 3/20 0.33
ALOX12 P18054 2/20 0.33
ACHE P22303 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL473352 0.98 ALDH1A1 (0.38) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL8157664 0.78 ALDH1A1 (0.38) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL5982527 0.78 ADRA2A (0.39) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL2268932 0.76 KCNH2 (0.38) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL650919 0.76 TSHR (0.59) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL10243715 0.76 ALDH1A1 (0.43) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL19660965 0.75 CYP3A4 (0.38) ALDH1A1ADRA2BTSHRALOX15CYP3A4
SCHEMBL10245022 0.74 CA1 (0.44) ALDH1A1ADRA2BTSHRKDM4EACHE
SCHEMBL10891476 0.74 SLC6A4 (0.43) ALDH1A1ADRA2AKCNH2PGRADRA2B
SCHEMBL11886646 0.74 CA1 (0.44) ALDH1A1ADRA2BTSHRKDM4EACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1848719-B1 [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES EXELIXIS INC (US) 2012-02-01 EP disclosed
US-7994172-B2 [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism EXELIXIS, INC. (US) 2011-08-09 US disclosed
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases EXELIXIS, INC. (US) 2008-08-07 US disclosed
EP-1848719-A1 [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2007-10-31 EP disclosed
WO-2006071819-A1 [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases PDPK1, MTOR, RPS6KA2 ALDH1A1 4083/4885ADRA2A 3700/4885KCNH2 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.